Guggenheim slashes price target on Teladoc Health Inc. [TDOC] – find out why.


Teladoc Health Inc. [NYSE: TDOC] loss -4.53% on the last trading session, reaching $61.69 price per share at the time. The company report on April 6, 2022 that Teladoc Health to Announce First Quarter 2022 Financial Results.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, announced that it will release first quarter 2022 results on Wednesday, April 27, 2022, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day.

Conference Call DetailsThe conference call can be accessed by dialing 1-844-200-6205 for U.S. participants, or 1-929-526-1599 for international participants, and referencing conference ID #843324; or via a live audio webcast that will be available online at

Teladoc Health Inc. represents 159.98 million in outstanding shares, while the company has a total market value of $10.49 billion with the latest information. TDOC stock price has been found in the range of $61.46 to $64.45.

If compared to the average trading volume of 4.46M shares, TDOC reached a trading volume of 2960859 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Teladoc Health Inc. [TDOC]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TDOC shares is $101.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TDOC stock is a recommendation set at 2.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Guggenheim have made an estimate for Teladoc Health Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on April 07, 2022. While these analysts kept the previous recommendation, Credit Suisse raised their target price to Outperform. The new note on the price target was released on April 01, 2022, representing the official price target for Teladoc Health Inc. stock. Previously, the target price had yet another raise to $95, while Argus analysts kept a Buy rating on TDOC stock. On February 23, 2022, analysts decreased their price target for TDOC shares from 83 to 74.

The Average True Range (ATR) for Teladoc Health Inc. is set at 4.60, with the Price to Sales ratio for TDOC stock in the period of the last 12 months amounting to 5.16. The Price to Book ratio for the last quarter was 0.62, with the Price to Cash per share for the same quarter was set at 5.27. Price to Free Cash Flow for TDOC in the course of the last twelve months was 56.56 with Quick ratio for the last quarter at 3.50.

Trading performance analysis for TDOC stock

Teladoc Health Inc. [TDOC] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -7.61. With this latest performance, TDOC shares dropped by -7.50% in over the last four-week period, additionally sinking by -55.86% over the last 6 months – not to mention a drop of -66.26% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TDOC stock in for the last two-week period is set at 41.90, with the RSI for the last a single of trading hit 38.10, and the three-weeks RSI is set at 43.48 for Teladoc Health Inc. [TDOC]. The present Moving Average for the last 50 days of trading for this stock 67.82, while it was recorded at 64.46 for the last single week of trading, and 109.10 for the last 200 days.

Teladoc Health Inc. [TDOC]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Teladoc Health Inc. [TDOC] shares currently have an operating margin of -11.76 and a Gross Margin at +57.96. Teladoc Health Inc.’s Net Margin is presently recorded at -21.09.

Return on Equity for this stock declined to -2.69, with Return on Assets sitting at -2.35.

Teladoc Health Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.50 and a Current Ratio set at 3.70.

An analysis of insider ownership at Teladoc Health Inc. [TDOC]

There are presently around $9,161 million, or 85.10% of TDOC stock, in the hands of institutional investors. The top three institutional holders of TDOC stocks are: ARK INVESTMENT MANAGEMENT LLC with ownership of 19,466,931, which is approximately 2.879% of the company’s market cap and around 0.50% of the total institutional ownership; VANGUARD GROUP INC, holding 13,140,062 shares of the stock with an approximate value of $849.11 million in TDOC stocks shares; and BAILLIE GIFFORD & CO, currently with $702.88 million in TDOC stock with ownership of nearly 23.528% of the company’s market capitalization.

Positions in Teladoc Health Inc. stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 351 institutional holders increased their position in Teladoc Health Inc. [NYSE:TDOC] by around 23,252,626 shares. Additionally, 384 investors decreased positions by around 17,224,247 shares, while 118 investors held positions by with 101,288,225 shares. The mentioned changes placed institutional holdings at 141,765,098 shares, according to the latest SEC report filing. TDOC stock had 113 new institutional investments in for a total of 7,705,380 shares, while 140 institutional investors sold positions of 8,057,283 shares during the same period.